CALQUENCE is a kinase inhibitor indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
\nThis indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.<\/p>\n
Calquence (acalabrutinib capsules) for oral use Initial U.S. Approval: 2017
\nTo access acalabrutinib capsules sold under the brand name can be made available on request to patient if the drug has not been approved or is not available in your country. For information or advice, call IPN’s Pharmaceutical Expert. Our expert will be happy to take your query and guide with an effective solution. Be free and call today for full support at +91 9891 296 838 (Mr. Tarun) \/ +91 9811 747 774 (Mr. Neeraj)<\/p>\n","protected":false},"excerpt":{"rendered":"
Calquence (acalabrutinib) is a medication used for the treatment of Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukaemia (CLL) and Small Lymphocytic Leukaemia (SLL).<\/p>\n
Disease Indications-Lymphoma If you have a prescription from a Registered Medical Practitioner (RMP),\u00a0IPN<\/a> in Delhi can assist you in obtaining access to genuine medication.\u00a0 Our professional will provide you with a step-by-step guide on how to legally and safely import “Acalabrutinib Capsules\u201d based on the information you provide.<\/strong><\/p>\n
\nManufacturer-AstraZeneca Pharmaceuticals LP
\nUsage-Oral
\nMedicine Approved By-European Medical Agency (EMA), Food and Drug Administration (FDA), Health Canada, Pharmaceuticals and Medical Devices Agency (PMDA), Therapeutic Goods Administration (TGA)
\nSummary of FDA-approved use on approval date: Click Here<\/a>
\n(see Drugs@FDA for complete indication)<\/p>\nAccess the best support services globally<\/h4>\n